Today, Sciety wants to pay attention to World TB Day, which aims to highlight the extensive health, social and economic…Read more
Sciety invests SEK 35 million in the company Elypta, which is developing a new method for early cancer diagnosis. The…Read more
Members in our network receive exclusive invitations to company presentations and advance information regarding those companies. There are no charges for belonging to the network. Investments are from TSEK 100 and upwards.
Sciety offers capital market services with a focus on Swedish life science. Based on extensive industry experience, we offer services to investors, growth companies and industrial players within life science.
What others think
“Athera chose to work with Sciety as they have an effective process for capital acquisition combined with specialist competence within life science and a strong network of investors. With the help of Sciety, Athera could execute their share issue in a short amount of time. Both management and owners are very satisfied with the cooperation with Sciety.
Carina Schmidt, CEO of Athera Biotechnologies
From late preclinical trial phase to Phase 2 Clinical Trials. All therapeutic areas.
From clinical validation phase to expansion phase.
From late preclinical phase to Phase 2 Clinical Trials. All therapeutic areas.
From clinical validation to expansion phase. All indications.
ICT in healthcare
From pilot phase to expansion phase. Value enhancing healthcare.
From early sales to expansion phase. Preventive care, keep fit activities and hospital care.
Companies for investment
Receive information about upcoming investment opportunities
Sign up to receive information about upcoming investment opportunities and invitations to investor lunches with the company's management.
Selection of executed investments
Cavis Technologies has developed a combined guidewire/catheter, Wirecath®, for diagnosis of people with coronary heart disease. Wirecath® is expected to provide important clinical benefits.
Elypta has developed a new method for early cancer diagnosis. Liquid Biopsy is a rapidly growing field that is expected to be of great importance for cancer diagnosis.
The company is in Phase II with a pharmaceutical candidate for a life-threatening illness for which there are currently no sufficient therapies.
Predicare is the company behind the system RETTS©, used by 95% of Sweden’s hospitals and ambulances. RETTS© daily helps healthcare professionals to make the right decisions in emergency situations.